(TSE 4539)
FY2021 First Quarter Business Summary
(Year Ending March 31, 2022)
Sales, Income
(¥mn) | ||||||||||
FY2020 | FY2021 | |||||||||
1Q | Distrib. | Full Year | 1Q | Distrib. | YOY | Full Year | Progress | |||
Amount | (%) | Amount | Amount | (%) | (%) | (Forecast) | Rate (%) | |||
Net sales | 7,196 | 100.0 | 31,541 | 7,575 | 100.0 | ― | 31,000 | 24.4 | ||
Pharmaceuticals | 7,146 | 99.3 | 30,423 | 7,377 | 97.4 | ― | ― | ― | ||
Others | 49 | 0.7 | 1,117 | 197 | 2.6 | ― | ― | ― | ||
Cost of sales | 4,640 | 64.5 | 20,097 | 5,529 | 73.0 | ― | ― | ― | ||
SG&A expenses | 2,589 | 36.0 | 10,879 | 2,071 | 27.3 | ― | ― | ― | ||
R&D expenses | 477 | 6.6 | 1,998 | 620 | 8.2 | ― | 2,400 | 25.9 | ||
Operating income/loss | (32) | ― | 564 | (26) | ― | ― | 350 | ― | ||
Income/Loss before income | ||||||||||
taxes and minority interests | (12) | ― | 713 | 15 | 0.2 | ― | ― | ― | ||
Net income/loss attributable to | ||||||||||
owners of the parent | 19 | 0.3 | 495 | (13) | ― | ― | 80 | ― |
Note:
We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021.
Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.
1
Pharmaceutical Sales
Generics, Proprietary Products and New Drugs | (¥mn) | |||||||||||
FY2020 | FY2021 | |||||||||||
1Q | Distrib. | Full Year | 1Q | Distrib. | YOY | Full Year | Progress | |||||
Amount | (%) | Amount | Amount | (%) | (%) | (Forecast) | Rate (%) | |||||
Total | 6,388 | 100.0 | 27,322 | 6,569 | 100.0 | ― | 26,550 | 24.7 | ||||
Generics | 6,109 | 95.6 | 25,532 | 6,111 | 93.0 | ― | 24,700 | 24.7 | ||||
To medical institutions | 5,860 | 24,531 | 5,817 | ― | 23,600 | 24.6 | ||||||
To other makers* | 248 | 1,000 | 294 | ― | 1,100 | 26.8 | ||||||
Proprietary products | 279 | 4.4 | 1,790 | 457 | 7.0 | ― | 1,850 | 24.7 | ||||
Uralyt | 184 | 730 | 156 | ― | 580 | 26.9 | ||||||
Others | 94 | 1,059 | 301 | ― | 1,270 | 23.8 | ||||||
Chemiphar, ODM Generics | (¥mn) | |||||||||||
FY2020 | FY2021 | |||||||||||
1Q | Distrib. | Full Year | 1Q | Distrib. | YOY | Full Year | Progress | |||||
Amount | (%) | Amount | Amount | (%) | (%) | (Forecast) | Rate (%) | |||||
Total | 6,506 | 100.0 | 26,696 | 6,337 | 100.0 | ― | 25,410 | 24.9 | ||||
Generics | 6,109 | 93.9 | 25,532 | 6,111 | 96.4 | ― | 24,700 | 24.7 | ||||
Generics (ODM) | 397 | 6.1 | 1,164 | 226 | 3.6 | ― | 710 | 31.8 |
* Includes exports.
Note:
We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021.
Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.
2
Sales Distribution
By Launch Year | (¥mn) | |||||
FY2020 | FY2021 | |||||
1Q | Distrib. | 1Q | Distrib. | YOY | ||
Amount | (%) | Amount | (%) | (%) | ||
FY2014 and before | 4,993 | 81.7 | 4,715 | 77.2 | ― | |
FY2015 | 251 | 4.1 | 272 | 4.5 | ― | |
FY2016 | 137 | 2.3 | 137 | 2.2 | ― | |
FY2017 | 336 | 5.5 | 368 | 6.0 | ― | |
FY2018 | 216 | 3.5 | 189 | 3.1 | ― | |
FY2019 | 29 | 0.5 | 32 | 0.5 | ― | |
FY2020 | 143 | 2.3 | 337 | 5.5 | ― | |
FY2021 | ― | ― | 59 | 1.0 | ― | |
Total | 6,109 | 100.0 | 6,111 | 100.0 | ― |
By Main Therapeutic Categories | (%) | |||
FY2020 | FY2021 | |||
1Q | 1Q | |||
Cardiovascular and respiratory drugs | 33.1 | 28.3 | ||
Digestive organ drugs | 16.1 | 15.6 | ||
Agents affecting metabolism | 16.0 | 15.4 | ||
Drugs for nervous system, sensory organs | 11.8 | 13.0 | ||
Antibiotics and chemotherapeutic drugs | 4.3 | 6.5 | ||
Antineoplastic agents | 3.3 | 2.5 | ||
Others | 17.4 | 18.7 |
Note:
We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021. Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.
3
Balance Sheet, per Share Information
Balance Sheet Data | (¥mn) | |||||||||||||
March 31, 2021 | June 30, 2021 | |||||||||||||
Amount | Amount | Change | ||||||||||||
Total assets | 47,124 | 48,127 | 1,002 | |||||||||||
Net assets | 18,014 | 17,907 | (107) | |||||||||||
Owned capital | 17,997 | 17,890 | (107) | |||||||||||
Capital-to-asset ratio (%) | 38.2 | 37.2 | (1.0) | |||||||||||
Current assets | 30,446 | 31,605 | 1,159 | |||||||||||
Current liabilities | 14,102 | 14,386 | 283 | |||||||||||
Current ratio (x) | 2.16 | 2.20 | 0.04 | |||||||||||
Per Share Information | (¥) | |||||||||||||
FY2020 | FY2021 | |||||||||||||
1Q | Full Year | 1Q | YOY | Full Year | ||||||||||
Amount | Amount | Amount | (Forecast) | |||||||||||
Earnings per share | 5.45 | 137.75 | (3.66) | ― | 22.25 | |||||||||
Full Year | ||||||||||||||
June 30, 2020 | March 31, 2021 | June 30, 2021 | (Forecast) | |||||||||||
Book value per share | 4,811.70 | 5,006.49 | 4,976.70 | 165.00 | ― | |||||||||
Dividends per share | ― | 50.00 | ― | ― | 50.00 | |||||||||
Dividend payout ratio (%) | ― | 36.3 | ― | ― | 224.7 | |||||||||
Note: | ||||||||||||||
We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021. | ||||||||||||||
Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated. |
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Nippon Chemiphar Co. Ltd. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 06:28:02 UTC.